Journal of Medicinal Chemistry
ARTICLE
’ AUTHOR INFORMATION
J. Infect. Dis. 2004, 189, 901–908. (d) Borrmann, S.; Lundgren, I.;
Oyakhirome, S.; Impouma, B.; Matsiegui, P. B.; Adegnika, A. A.; Issifou,
S.; Kun, J. F.; Hutchinson, D.; Wiesner, J.; Jomaa, H.; Kremsner, P. G.
Fosmidomycin plus clindamycin for treatment of pediatric patients aged
1 to 14 years with Plasmodium falciparum malaria. Antimicrob. Agents
Chemother. 2006, 50, 2713–2718. (e) Borrmann, S.; Adegnika, A. A.;
Moussavou, F.; Oyakhirome, S.; Esser, G.; Matsiegui, P. B.; Ramharter,
M.; Lundgren, I.; Kombila, M.; Issifou, S.; Hutchinson, D.; Wiesner, J.;
Jomaa, H.; Kremsner, P. G. Short-course regimens of artesunate-
fosmidomycin in treatment of uncomplicated Plasmodium falciparum
malaria. Antimicrob. Agents Chemother. 2005, 49, 3749–3754. (f)
Oyakhirome, S.; Issifou, S.; Pongratz, P.; Barondi, F.; Ramharter, M.;
Kun, J. F.; Missinou, M. A.; Lell, B.; Kremsner, P. G. Randomized
controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyri-
methamine in the treatment of Plasmodium falciparum malaria. Anti-
microb. Agents Chemother. 2007, 51, 1869–1871.
Corresponding Author
*Address: Department of Pharmacology, Baylor College of
Medicine, 1 Baylor Plaza, Houston, TX 77030. Tel: 713-798-7415.
E-mail: ysong@bcm.edu.
Author Contributions
§These authors contributed equally.
’ ACKNOWLEDGMENT
This work was supported by a grant (R21AI088123) from the
National Institute of Allergy and Infectious Diseases (NIAID) to
Y.S., grants AI049151 and AI065357 from NIAID to D.C.C., and
a grant (Q1279) from Robert Welch Foundation to B.V.V.P. The
recombinant M. tuberculosis DXR expression plasmid was kindly
provided by Dr. T. Alwyn Jones (Uppsala University, Sweden).
We thank the staff of the X-ray Crystallography Facility at Baylor
College of Medicine for assistance in data collection.
(6) Sakamoto, Y.; Furukawa, S.; Ogihara, H.; Yamasaki, M. Fosmido-
mycin resistanceinadenylate cyclase deficient (cya) mutants of Escherichia
coli. Biosci. Biotechnol. Biochem. 2003, 67, 2030–2033.
(7) Brown, A. C.; Parish, T. DXR is essential in Mycobacterium
tuberculosis and fosmidomycin resistance is due to a lack of uptake. BMC
Microbiol. 2008, 8, 78–86.
(8) For development based on fosmidomycin, see(a) Shtannikov,
A. V.;Sergeeva, E. E.; Biketov, S. F.; Ostrovskii, D. N. Evaluation ofin vitro
antibacterial activity of fosmidomycin and its derivatives. Antibiot. Khimioter
2007, 52, 3–9. (b) Kuntz, L.; Tritsch, D.; Grosdemange-Billiard, C.;
Hemmerlin, A.; Willem, A.; Bach, T. J.; Rohmer, M. Isoprenoid biosynthesis
as a target for antibacterial and antiparasitic drugs: phosphonohydroxa-
mic acids as inhibitors of deoxyxylulose phosphate reducto-isomerase.
Biochem. J. 2005, 386, 127–135. (c) Merckle, L.; de Andres-Gomez, A.;
Dick, B.; Cox, R. J.; Godfrey, C. R. A fragment-based approach to
understanding inhibition of 1-deoxy-D-xylulose-5-phosphate reducto-
isomerase. ChemBioChem 2005, 6, 1866–1874. (d) Munos, J. W.; Pu, X.;
Liu, H. W. Synthesis and analysis of a fluorinated product analogue as an
inhibitor for 1-deoxy-D-xylulose 5-phosphate reductoisomerase. Bioorg.
Med. Chem. Lett. 2008, 18, 3090–3094. (e) Ortmann, R.; Wiesner, J.;
Silber, K.; Klebe, G.; Jomaa, H.; Schlitzer, M. Novel deoxyxylulosepho-
sphate-reductoisomerase inhibitors: fosmidomycin derivatives with
spacious acyl residues. Arch. Pharm. (Weinheim) 2007, 340, 483–490.
(f) Silber, K.; Heidler, P.; Kurz, T.; Klebe, G. AFMoC enhances
predictivity of 3D QSAR: a case study with DOXP-reductoisomerase.
J. Med. Chem. 2005, 48, 3547–3563. (g) Woo, Y. H.; Fernandes, R. P.;
Proteau, P. J. Evaluation of fosmidomycin analogs as inhibitors of the
Synechocystis sp. PCC6803 1-deoxy-D-xylulose 5-phosphate reducto-
isomerase. Bioorg. Med. Chem. 2006, 14, 2375–2385. (h) Kurz, T.;
Schl€uter, K.; Kaula, U.; Bergmann, B.; Walter, R. D.; Geffken, D.
Synthesis and antimalarial activity of chain substituted pivaloyloxy-
methyl ester analogues of Fosmidomycin and FR900098. Bioorg. Med.
Chem. 2006, 14, 5121–5135. (i) Kurz, T.; Schl€uter, K.; Pein, M.;
Behrendt, C.; Bergmann, B.; Walter, R. D. Conformationally restrained
aromatic analogues of fosmidomycin and FR900098. Arch. Pharm.
Chem. Life Sci. 2007, 340, 339–344. (j) Haemers, T.; Wiesner, J.; Van
Poecke, S.; Goeman, J.; Henschker, D.; Beck, E.; Jomaa, H.; Van
Calenbergh, S. Synthesis of R-substituted fosmidomycin analogues as
highly potent Plasmodium falciparum growth inhibitors. Bioorg. Med.
Chem. Lett. 2006, 16, 1888–1891. (k) Devreux, V.; Wiesner, J.; Jomaa,
H.; Rozenski, J.; Van der Eycken, J.; Van Calenbergh, S. Divergent
strategy for the synthesis of R-aryl-substituted fosmidomycin analogues.
J. Org. Chem. 2007, 72, 3783–3789.
’ ABBREVIATIONS
DXR, 1-deoxy-D-xylulose-5-phosphate reductoisomerase;EcDXR,
DXR from E. coli; MtDXR, DXR from Mycobacterium tuberculosis;
DXP, 1-deoxy-D-xylulose-5-phosphate; IPP, isopentenyl dipho-
sphate; DMAPP, dimethylallyl diphosphate; MEP, 2-C-methyl-
D-erythritol-4-phosphate; SAR, structure activity relationship;
QSAR, quantitative structure activity relationship.
’ REFERENCES
(1) See a recent review and the references cited therein:Hunter,
W. N. The non-mevalonate pathway of isoprenoid precursor biosynth-
esis. J. Biol. Chem. 2007, 282, 21573–21577.
(2) (a) Singh, N.; Cheve, G.; Avery, M. A.; McCurdy, C. R. Target-
ing the methyl erythritol phosphate (MEP) pathway for novel anti-
malarial, antibacterial and herbicidal drug discovery: inhibition of
1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) enzyme.
Curr. Pharm. Des. 2007, 13, 1161–1177. (b) Rodriguez-Concepcion,
M. The MEP pathway: a new target for the development of herbicides,
antibiotics and antimalarial drugs. Curr. Pharm. Des. 2004, 10, 2391–2400.
(b) Testa, C. A.; Brown, M. J. The methylerythritol phosphate pathway
and its significance as a novel drug target. Curr. Pharm. Biotechnol. 2003,
4, 248–259. (d) Dhiman, R. K.; Schaeffer, M. L.; Bailey, A. M.; Testa,
C. A.; Scherman, H.; Crick, D. C. 1-Deoxy-D-xylulose 5-phosphate
reductoisomerase (IspC) fromMycobacteriumtuberculosis: towardsunder-
standing mycobacterial resistance to fosmidomycin. J. Bacteriol. 2005,
187, 8395–8402.
(3) Kuzuyama, T.; Shimizu, T.; Takahashi, S.; Seto, H. Fosmido-
mycin, a specific inhibitor of 1-deoxy-D-xylulose 5-phosphate reducto-
isomerase in the nonmevalonate pathway for terpenoid biosynthesis.
Tetrahedron Lett. 1998, 39, 7913–7916.
(4) Mine, Y.; Kamimura, T.; Nonoyama, S.; Nishida, M.; Goto, S.;
Kuwahara, S. In vitro and in vivo antibacterial activities of FR-31564, a
new phosphonic acid antibiotic. J. Antibiot. (Tokyo) 1980, 33, 36–43.
(5) (a) Jomaa, H.; Wiesner, J.; Sanderbrand, S.; Altincicek, B.;
Weidemeyer, C.; Hintz, M.; Turbachova, I.; Eberl, M.; Zeidler, J.;
Lichtenthaler, H. K.; Soldati, D.; Beck, E. Inhibitors of the nonmevalo-
nate pathway of isoprenoid biosynthesis as antimalarial drugs. Science
1999, 285, 1573–1576. (b) Missinou, M. A.; Borrmann, S.; Schindler, A.;
Issifou, S.; Adegnika, A. A.; Matsiegui, P. B.; Binder, R.; Lell, B.; Wiesner,
J.; Baranek, T.; Jomaa, H.; Kremsner, P. G. Fosmidomycin for malaria.
Lancet 2002, 360, 1941–1942. (c) Borrmann, S.; Adegnika, A. A.;
Matsiegui, P. B.; Issifou, S.; Schindler, A.; Mawili-Mboumba, D. P.;
Baranek, T.; Wiesner, J.; Jomaa, H.; Kremsner, P. G. Fosmidomycin-
clindamycin for Plasmodium falciparum infections in African children.
(9) For nonfosmidomycin-like inhibitors, see(a) Yajima, S.; Hara,
K.; Sanders, J. M.; Yin, F.; Ohsawa, K.; Wiesner, J.; Jomaa, H.; Oldfield,
E. Crystallographic structures of two bisphosphonate:1-deoxyxylulose-
5-phosphate reductoisomerase complexes. J. Am. Chem. Soc. 2004,
126, 10824–10825. (b) Deng, L.; Sundriyal, S.; Rubio, V.; Shi, Z.;
Song, Y. Coordination chemistry based approach to lipophilic inhibi-
tors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase. J. Med. Chem.
2009, 52, 6539–6542. (c) Deng, L.; Endo, K.; Kato, M.; Cheng, G.;
Yajima, S.; Song, Y. Structures of 1-deoxy-D-xylulose-5-phosphate
4733
dx.doi.org/10.1021/jm200363d |J. Med. Chem. 2011, 54, 4721–4734